Grriz JL, Soler MJ, Navarro-Gonzlez JF, Garca-Carro C, Puchades MJ, Dmarco L, et al
The argument for coverage is that retatrutide is durable enough to push patients out of obesity entirely in two thirds of cases which over a decade is cheaper than treating the cardiovascular, metabolic, and orthopedic complications of long-term obesity
Long-acting formulations, such as dulaglutide, liraglutide, and once-weekly exenatide, have consistently shown superior efficacy in reducing both fasting plasma glucose and HbA1c levels when compared to shorter-acting alternatives like twice-daily exenatide and lixisenatide (Htike et al
Blood pressure should stabilize
It works by slowing digestion, curbing hunger, and helping you eat less while still keeping you feeling satisfied
A small subset of participants, approximately 12%, continued losing through week 48 without plateauing